Press Releases

Sep 05, 2024

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2024

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 15, 2024

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 11, 2024

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

Jul 08, 2024

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

May 09, 2024

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

May 07, 2024

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Apr 22, 2024

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 16, 2024

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Mar 13, 2024

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing